Literature DB >> 24052002

Clozapine-associated pneumonia and respiratory arrest secondary to severe constipation.

Nuwan Galappathie1, Sobia Khan.   

Abstract

Clozapine is often the drug of choice within patients suffering from treatment-resistant paranoid schizophrenia. It has a complex side effects profile which includes potentially fatal agranulocytosis. Clozapine has also become increasingly associated with a range of other side effects including constipation and pneumonia. We report on a case of clozapine-induced severe constipation leading to a silent presentation of pneumonia with a subsequent respiratory arrest. To our knowledge, this is the first case report of pneumonia secondary to severe constipation occurring in the absence of respiratory aspiration of feculent vomitus. We suggest a new pathological mechanism by way of severe constipation leading to diaphragmatic dysfunction and subsequent clozapine-induced pneumonia. In addition, implications for clinical practice are outlined.

Entities:  

Keywords:  clozapine; constipation; pneumonia; respiratory arrest; schizophrenia

Mesh:

Substances:

Year:  2013        PMID: 24052002     DOI: 10.1177/0025802413497708

Source DB:  PubMed          Journal:  Med Sci Law        ISSN: 0025-8024            Impact factor:   1.266


  2 in total

Review 1.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06

Review 2.  Fecal impaction: a systematic review of its medical complications.

Authors:  Blanca Serrano Falcón; Marta Barceló López; Beatriz Mateos Muñoz; Angel Álvarez Sánchez; Enrique Rey
Journal:  BMC Geriatr       Date:  2016-01-11       Impact factor: 3.921

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.